Aileen Ryan was named Vice President, Regulatory Affairs in July 2006. She has over twenty years of regulatory experience in the pharmaceutical/biotech industry and has been responsible for developing and implementing regulatory strategies for a wide variety of products. Prior to joining Vion, she was the head of Global Regulatory Strategy, Oncology for Bayer Pharmaceuticals Corporation since 2004. At Bayer, she was responsible for the global regulatory strategy for a portfolio of oncology compounds, including Nexavar® (sorafenib) Tablets, Bayer’s multi-kinase inhibitor for the treatment of advanced renal cell carcinoma, which was approved by the FDA in December 2005 and EMEA in 2006.

Prior to joining Bayer, Ms. Ryan was Vice President, Regulatory Affairs for Coley Pharmaceutical Group from 1999 to 2003. From 1993 to 1999, Ms. Ryan was Vice President of Regulatory Affairs and Compliance at ASTA Medica, Inc. From 1988 to 1993, she was a regulatory consultant. She began her career at Revlon Health Care Group (now Sanofi-Aventis) in the research laboratories.

Ms. Ryan holds a BS in biochemistry from the University of Massachusetts and an MS in Basic Medical Sciences from New York Medical College.